Published June 23, 2026
| Version v1
Thesis
Open
Psychometric hepatic encephalopathy score for diagnosis of minimal hepatic encephalopathy in cirrhosis of liver
Authors/Creators
-
1.
BLDE (Deemed to be University)
Description
BACKGROUND:
• Minimal hepatic encephalopathy (MHE) is a subclinical condition in liver cirrhosis
patients, often preceding overt hepatic encephalopathy (OHE).
• MHE impairs driving ability and quality of life but requires specialized
neuropsychological tests (e.g., PHES) for diagnosis, as routine exams are insufficient.
Aim
• Establish normative PHES values and assess its diagnostic efficacy for MHE in cirrhosis
patients.
Methods
• Study Design: Cross-sectional study (May 2023–December 2025) at BLDE(DU)
Medical College, Vijayapura.
• Participants: 166 cirrhosis patients (cases) and controls. Overt HE patients were
excluded.
• Assessments:
o PHES battery (NCT-A, NCT-B, SDT, LTT, DST) administered in a controlled
setting.
o Biochemical tests (ALT, AST, INR, albumin, etc.) and imaging (USG
abdomen/pelvis).
o MHE diagnosis: PHES score <−4 based on healthy nomograms.
Results
• Demographics: Cases were older (p=0.003) and predominantly male (92.77% vs.
67.47%, p<0.001). No educational differences (p=0.263).
10
Docusign Envelope ID: 282C8ADC-32EB-4351-8A18-26F1F561F16A
• Cognitive Performance: Cases showed significant impairment in all PHES subtests
(p<0.001) and lower mean PHES (−4.40 vs. 2.28, p<0.001).
• MHE Prevalence: 37.35% of cases had MHE; none in controls (p<0.001).
• Biochemical Markers: No correlation between ammonia levels and MHE status.
Conclusion
PHES is a reliable, non-invasive tool for early MHE detection in cirrhosis, aiding timely
intervention. While it should complement clinical evaluation, its cost-effectiveness and
accessibility enhance patient management and outcomes.
Files
22BMMED09.pdf
Additional details
Dates
- Created
-
2026-06-22
References
- 1.Li SW. Psychometric hepatic encephalopathy score for diagnosis of minimal hepatic encephalopathy in China. World Journal of Gastroenterology. 2013;19(46):8745. 2.Pawar VB, Surude RG, Sonthalia N, Zanwar V, Jain S, Contractor Q, et al. Minimal Hepatic Encephalopathy in Indians: Psychometric Hepatic Encephalopathy Score and Inhibitory Control Test for Diagnosis and Rifaximin or Lactulose for Its Reversal. Journal of Clinical and Translational Hepatology. 2019 Nov 27;7(X):1–9. 3.Weissenborn K. PHES: One label, different goods?! Journal of Hepatology. 2008 Sep;49(3):308 12. 4.Ma PR. [Normality tables of the population in Cuba for the psychometric tests used in the diagnosis of minimal hepatic encephalopathy]. PubMed. 2016 May 2;36(1):29–34. 5.Djomatcho LP, Mathurin Pierre Kowo, Antonin Ndjitoyap Ndam, Sylvain, Gabin Ulrich Kenfack, Firmin Ankouane Andoulo, et al. Normalisation of the psychometric encephalopathy score within the Cameroonian population. BMC Gastroenterology. 2021 Jul 12;21(1). 6.Zhan T, Stremmel W. The Diagnosis and Treatment of Minimal Hepatic Encephalopathy. Deutsches Aerzteblatt Online. 2012 Mar 9; 7.Rose CF, Amodio P, Bajaj JS, Dhiman RK, Montagnese S, Taylor-Robinson SD, et al. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. Journal of Hepatology [Internet]. 2020 Dec 1;73(6):1526–47. Available from: https://www.journal-of hepatology.eu/article/S0168-8278(20)30466-9/fulltext#back-bib8 8.Amodio P. Hepatic encephalopathy: Diagnosis and management. Liver International. 2018 Apr 24;38(6):966–75. 9. Bellafante D, Gioia S, Faccioli J, Riggio O, Ridola L, Nardelli S. The Management of Hepatic Encephalopathy from Ward to Domiciliary Care: Current Evidence and Gray Areas. Journal of Clinical Medicine [Internet]. 2023 Dec 27;13(1):166–6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10780160/ 10. Mahsa Khodadoostan, Sadeghian S, Safaei A, Kabiri M, Shavakhi S, Shavakhi AR, et al. Detection of Minimal Hepatic Encephalopathy in Iranian Patients with Cirrhosis. Middle East Journal of Digestive Diseases. 2018 Sep 4;10(4):230–5. 79 Docusign Envelope ID: 282C8ADC-32EB-4351-8A18-26F1F561F16A 11. Chen HJ, Chen R, Yang M, Teng GJ, Herskovits EH. Identification of Minimal Hepatic Encephalopathy in Patients with Cirrhosis Based on White Matter Imaging and Bayesian Data Mining. American Journal of Neuroradiology. 2014 Dec 11;36(3):481–7. 12.Suraweera D, Sundaram V, Saab S. Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions. Gut and Liver. 2016 Jul 15;10(4):509–19. 13. Abid S, Kamran M, Abid A, Butt N, Awan S, Abbas Z. Minimal Hepatic Encephalopathy: Effect of H. pylori infection and small intestinal bacterial overgrowth treatment on clinical outcomes. Scientific Reports. 2020 Jun 22;10(1). 14. Rega D, Aiko M, Nicolás Peñaranda, Urios A, Gallego JJ, Giménez-Garzó C, et al. Patients with Minimal Hepatic Encephalopathy Show Altered Thermal Sensitivity and Autonomic Function. Journal of Clinical Medicine. 2021 Jan 11;10(2):239–9. 15. Córdoba J. New assessment of hepatic encephalopathy. Journal of Hepatology. 2011 May;54(5):1030–40 16. Ferenci P. Hepatic encephalopathy. Gastroenterology Report [Internet]. 2017;5(2):138–47. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421503/ 17. Jeong JY, Jun DW, Bai D, Kim JY, Sohn JH, Ahn SB, et al. Validation of a Paper and Pencil Test Battery for the Diagnosis of Minimal Hepatic Encephalopathy in Korea. Journal of Korean Medical Science. 2017 Jan 1;32(9):1484–4. 18. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014 Jul 8;60(2):715–35. 19. Mrinmay Kumar Podder, Aftab H, Khalil MM, Hossain MI, Hossain MI, Ullah P, et al. Determination of normative value of Psychometric hepatic encephalopathy score in Bangladeshi volunteers. Journal of Bangladesh College of Physicians and Surgeons. 2023 Oct 26;41(4):277–81. 20. Pérez-Matos MC, Jiang ZG, Tapper EB. Factors That Affect Results of Psychometric Tests to Identify Patients With Minimal Hepatic Encephalopathy. Clinical Gastroenterology and Hepatology. 2018 Nov;16(11):1836–8. 21.Bajaj JS. Minimal hepatic encephalopathy matters in daily life. World Journal of Gastroenterology. 2008;14(23):3609. 80 Docusign Envelope ID: 282C8ADC-32EB-4351-8A18-26F1F561F16A 22.Bothara SS, Parihar P, Patil R. Advancements in Interventional Radiology for Managing Hepatic Encephalopathy: A Comprehensive Review. Cureus. 2024 Jun 19; 23.Pawar VB, Surude RG, Sonthalia N, Zanwar V, Jain S, Contractor Q, et al. Minimal Hepatic Encephalopathy in Indians: Psychometric Hepatic Encephalopathy Score and Inhibitory Control Test for Diagnosis and Rifaximin or Lactulose for Its Reversal. Journal of Clinical and Translational Hepatology. 2019 Nov 27;7(X):1–9. 24. Gazda J, Drotar P, Drazilova S, Gazda J, Gazda M, Janicko M, et al. Artificial Intelligence and Its Application to Minimal Hepatic Encephalopathy Diagnosis. Journal of Personalized Medicine. 2021 Oct 26;11(11):1090. 25. Ehrenbauer AF, Schneider H, Stockhoff L, Tiede A, Lorenz C, Dirks M, et al. Predicting overt hepatic encephalopathy after TIPS: Value of three minimal hepatic encephalopathy tests. JHEP Reports. 2023 Jun 28;5(9):100829–9. 26. Sharma B, Sharma P. Predictors of minimal hepatic encephalopathy in patients with cirrhosis. Saudi Journal of Gastroenterology. 2010;16(3):181. 27. Bale A, Pai CG, Shetty S, Girisha Balaraju, Shetty A. Prevalence of and Factors Associated With Minimal Hepatic Encephalopathy in Patients With Cirrhosis of Liver. Journal of Clinical and Experimental Hepatology. 2017 Jun 21;8(2):156–61. 28. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014 Jul 8;60(2):715–35. 29. Sharma P, Kumar A. Minimal hepatic encephalopathy in patients with cirrhosis by measuring liver stiffness and hepatic venous pressure gradient. Saudi Journal of Gastroenterology. 2012;18(5):316. 30. Shawcross DL, Dunk AA, Jalan R, Kircheis G, de Knegt RJ, Laleman W, et al. How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist. European Journal of Gastroenterology & Hepatology [Internet]. 2016 Feb 1 [cited 2021 Mar 25];28(2):146–52. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885589/ 31. Bajaj JS, Wade JB, Gibson DP, Heuman DM, Thacker LR, Sterling RK, et al. The Multi Dimensional Burden of Cirrhosis and Hepatic Encephalopathy on Patients and Caregivers. American Journal of Gastroenterology. 2011 Sep;106(9):1646–53. 81 Docusign Envelope ID: 282C8ADC-32EB-4351-8A18-26F1F561F16A 32. Ortiz M, Córdoba J, Jacas C, Flavià M, Esteban R, Guardia J. Neuropsychological abnormalities in cirrhosis include learning impairment. Journal of Hepatology. 2006 Jan;44(1):104–10. 33. Weissenborn K, Ennen JC, Schomerus H, Rückert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. Journal of Hepatology. 2001 May;34(5):768–73. 34. Ortiz M, Jacas C, Córdoba J. Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. Journal of Hepatology. 2005 Apr;42(1):S45–53. 35. Sahu P, Chhabra P, Mehendale AM. A Comprehensive Review on Non-Alcoholic Fatty Liver Disease. Curēus [Internet]. 2023 Dec 8 [cited 2024 May 13]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10771633/ 36.Cuko L, Bele S, Babameto A, Tafaj I, Hysenj A, Shagla E, et al. Direct-Acting Antiviral Treatment in Albanian Patients With Chronic Hepatitis C and Advanced Liver Fibrosis. Cureus. 2022 Dec 17; 37. Migita K, Seiji Miyazoe, Maeda Y, Manabu Daikoku, Seigo Abiru, Ueki T, et al. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection—association between TGF-β1 polymorphisms and hepatocellular carcinoma. Journal of Hepatology. 2005 Apr 1;42(4):505–10. 38. Nakamura A, Yoshimura T, Ichikawa T. Liver Disease-Related Sarcopenia: A Predictor of Poor Prognosis by Accelerating Hepatic Decompensation in Advanced Chronic Liver Disease. Cureus. 2023 Nov 19; 39. Islam R, Kundu S, Jha SB, Ana Leonor Rivera, Vanessa G, Islam H, et al. Cirrhosis and Coagulopathy: Mechanisms of Hemostasis Changes in Liver Failure and Their Management. Cureus [Internet]. 2022 Apr 3;14(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063731/ 40. Parav Tantia, Aggarwal P, Acharya S, Kumar S, Kothari M, Kadam A, et al. Exploring Haematological Complications in Cirrhosis of the Liver: A Comprehensive Review. Cureus. 2024 Jul 24; 41.Bleeding Esophageal Varices: Portal Hypertension. Archives of Internal Medicine. 1960 Jul 1;106(1):156. 42. Dardari L, Taha M, Dahat P, Toriola S, Satnarine T, Zohara Z, et al. The Efficacy of Carvedilol in Comparison to Propranolol in Reducing the Hepatic Venous Pressure Gradient and Decreasing the Risk of Variceal Bleeding in Adult Cirrhotic Patients: A Systematic Review. Cureus [Internet]. 2023;15(8):e43253. 43. Anand U, Kumar R, Priyadarshi RN, Parasar K, John AG. Proximal Splenorenal Shunt Surgery for Bleeding Gastric Varices in Non-Cirrhotic Portal Hypertension. Cureus. 2020 Sep 15; 82 Docusign Envelope ID: 282C8ADC-32EB-4351-8A18-26F1F561F16A 44. Tiwari PS, KC S, Sharma D, Paudel MS, Mandal A. Prevalence of Portal Hypertensive Gastropathy in Chronic Liver Disease and Correlation with the Severity of Liver disease. Cureus. 2019 Aug 21; 45. Danish M, Ismail H, Tulsi R, Mehmood N, Laeeq SM, Hassan Luck N. Liver Elastography as a Predictor of Esophageal Varices in Patients With Cirrhosis. Cureus. 2021 Oct 8; 46. Asemota J, Saleh M, Igbinovia O, Burns D. A Concise Review on Current Trends in Imaging and Surgical Management of Hepatocellular Carcinoma. Cureus. 2020 Jul 14; 47. Roy P, Naofel Minhaz, Shah-Riar P, Simona SY, Tasniem Tasha, Tahira Binte Hasan, et al. A Comprehensive Systematic Review of the Latest Management Strategies for Hepatorenal Syndrome: A Complicated Syndrome to Tackle. Cureus. 2023 Aug 7; 48. Santhosh Raja Thangaraj, Srinivasan M, Hadia Arzoun, Thomas SS. A Systematic Review of the Emerging Treatment for Hepatorenal Syndrome With a Principal Focus on Terlipressin: A Recent FDA-Approved Drug. Cureus [Internet]. 2023 Jul 24 [cited 2023 Oct 16]; Available from: https://doi.org/10.7759%2Fcureus.42367